Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Search
Search results
Let’s talk about tech
As people living with sight loss we are constantly looking for solutions to make our lives easier without too much effort or cost writes Jonathan Abro.
Stem cells
Stem cells are a special type of cell, which under the right conditions can be encouraged to grow into any other type of cell in the body, including retinal cells (rods, cones and retinal pigment epithelial cells).
A new approach to treating inherited sight loss
A new approach to treating inherited sight loss
From isolation to exploration: what you can do to build your confidence when travelling
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
From isolation to exploration
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Therapy development updates
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Meet our supporters: William Taylor
Fundraising for Retina UK means a lot to me - both my dad and my nephew have been affected by inherited sight-loss, and I've seen first-hand the incredible work this charity does.
Potential drug targets identified for RP
A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.